[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019005572A - Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia. - Google Patents

Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia.

Info

Publication number
MX2019005572A
MX2019005572A MX2019005572A MX2019005572A MX2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A MX 2019005572 A MX2019005572 A MX 2019005572A
Authority
MX
Mexico
Prior art keywords
diabetes
treating type
medicinal complex
diabetic dyslipidemia
medicinal
Prior art date
Application number
MX2019005572A
Other languages
Spanish (es)
Inventor
Sook Park Ki
Jin Yoon Hye
Hyuk Jung Jong
Won Kim Sung
Yoon Kim Ji
Cheol Yoo Seok
Sun Kim Ri
Soon Ahn Jae
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2019005572A publication Critical patent/MX2019005572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a medicinal complex for effectively treating type 2 diabetes and dyslipidemia of diabetic patients, more specifically, the present invention provides a medicinal complex comprising a peptidase IV inhibitor gemigliptin or a pharmaceutically acceptable salt thereof, and a HMG-CoA reductase inhibitor rosuvastatin or a pharmaceutically acceptable salt thereof, to effectively control blood sugar levels and improve cardiovascular disease risk factors.
MX2019005572A 2016-11-15 2017-11-15 Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia. MX2019005572A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160152195 2016-11-15
PCT/KR2017/012941 WO2018093144A1 (en) 2016-11-15 2017-11-15 Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia

Publications (1)

Publication Number Publication Date
MX2019005572A true MX2019005572A (en) 2019-08-14

Family

ID=62146049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005572A MX2019005572A (en) 2016-11-15 2017-11-15 Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia.

Country Status (9)

Country Link
KR (1) KR102055894B1 (en)
CN (1) CN109996545A (en)
BR (1) BR112019009709A2 (en)
CO (1) CO2019005207A2 (en)
MX (1) MX2019005572A (en)
PE (1) PE20191502A1 (en)
PH (1) PH12019501028A1 (en)
RU (1) RU2721406C1 (en)
WO (1) WO2018093144A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
CA2599419A1 (en) * 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
AU2010281913A1 (en) * 2009-08-13 2012-04-05 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
EA034869B1 (en) * 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Treatment of genotyped diabetic patients with dpp-4 inhibitors such as linagliptin
EP2566465A2 (en) * 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
KR20140013436A (en) * 2012-07-24 2014-02-05 한미약품 주식회사 Composite formulation for oral administration comprising metformin and rosuvastatin
UY35065A (en) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
TW201636015A (en) * 2013-07-05 2016-10-16 卡地拉保健有限公司 Synergistic compositions
CN103494788B (en) * 2013-10-10 2015-08-05 齐晓彤 Pharmaceutical composition of rosuvastatin calcium tablets and preparation method thereof
CN104473929B (en) * 2014-12-17 2018-05-29 深圳翰宇药业股份有限公司 A kind of Xi Gelieting simvastatin slow-releases composition

Also Published As

Publication number Publication date
KR20180054500A (en) 2018-05-24
CO2019005207A2 (en) 2019-08-20
KR102055894B1 (en) 2019-12-13
RU2721406C1 (en) 2020-05-19
PH12019501028A1 (en) 2020-01-20
CN109996545A (en) 2019-07-09
PE20191502A1 (en) 2019-10-22
BR112019009709A2 (en) 2019-08-13
WO2018093144A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2019011117A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof.
EP3589628A4 (en) Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2019014410A (en) Methods of treating fabry patients having renal impairment.
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
MX347372B (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator.
EA201490721A1 (en) Drug for the treatment of diseases of the anterior chamber of the eye, including rebamipid and tear-retaining agent
PH12015500434A1 (en) Combination of sglt2 inhibitors and anti-hypertensive drugs
JOP20210201A1 (en) Blood glucose lowering compound
EP3922264A4 (en) Pharmaceutical composition for preventing, ameliorating or treating skin disease
WO2015022530A3 (en) Materials and methods relating to pancreatic cancer
MX2021007477A (en) Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer.
WO2012099448A3 (en) RECOMBINANT ADENOVIRUS EXPRESSING αA-CRYSTALLIN GENE AND GENE THERAPY FOR RETINAL VASCULAR DISEASE USING SAME
PH12019501028A1 (en) Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
MX2019014988A (en) Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus.
EP4374918A3 (en) Methods of treating fabry patients having renal impairment
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
CA3199014A1 (en) Combination therapy for the treatment of a liver disease
PH12020500295A1 (en) Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same
MX2015014939A (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias.
EP3669880A4 (en) USE OF miR-18b FOR PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE DISEASE AND NEUROMUSCULAR DISEASE
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity